Similarly, although in the KEYNOTE-042 trial [8], the OS improvement deriving from pembrolizumab over chemotherapy was demonstrated in the overall cohort with PD-L1 ≥ 1%, the observed benefit was mainly driven by PD-L1 overexpressing cases, which represents in clinical practice only one-third of the overall population of NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.